Douglas Lin, MD PhD retweeted
Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications
onlinelibrary.wiley.com/doi/…
BRCA1/2🧬 reversion mutations, which restore BRCA function and confer PARP inhibitor resistance, were identified in advanced #ProstateCancer both after and without prior PARP inhibitor exposure.
In this retrospective liquid biopsy study, 30% of PARP-naïve patients with BRCA reversions had received chemotherapy and radiation, suggesting DNA-damaging therapies may promote reversion and primary resistance, supporting earlier PARP inhibitor use.
@DougLinMD
@MaxMaomaoYe
@OGjoerup
@RyonGraf
@RichardHuangMD
@DouglasMab3lt
@DrRanaMcKay
@OncoAlert 🚨
@silkegillessen
@AOmlin
@weoncologists
Douglas Lin, MD PhD retweeted
Have you seen this newly recognized WHO tumor entity? I’m delighted to share this comprehensive review just published @Human_Pathology (PMID: 41475433), beautifully written by Gahie, Hui-Min, and my colleagues @BrownPathology
Endometrial gastric (gastrointestinal) -type mucinous adenocarcinoma (EGMA) is a rare histologic subtype of endometrial carcinoma that has recently included as a new WHO entity and is now recognized by the 2023 FIGO staging system as an aggressive histologic subtype. Previously, these tumors often overlapped diagnostically with endometrioid carcinomas showing mucinous differentiation; however, EGMA is now clearly established as a distinct clinicopathologic entity with more aggressive behavior.
Morphologically, tumor cells show gastric and/or intestinal differentiation with variable cytologic atypia.
Immunohistochemically, ER and PR are negative or only focally positive (<5%), while tumor cells express gastrointestinal markers, including CDX2, MUC6, HIK1083, and SATB2. Clinically, EGMA is associated with a higher likelihood of deep myometrial invasion, lymphovascular invasion, and lymph node metastasis.
At present, complete surgical resection - including hysterectomy with bilateral salpingo-oophorectomy, tumor debulking, with or without pelvic/paraaortic lymph node dissection -appears to be the most effective primary treatment. Adjuvant chemotherapy is also likely beneficial, particularly for higher-stage disease.
This review emphasizes the importance of judicious use of immunohistochemistry, careful morphologic evaluation, and close correlation with clinical history to accurately diagnose EGMA and distinguish it from important mimics.
🔗 Full article is available at the following link:
sciencedirect.com/science/ar…
Douglas Lin, MD PhD retweeted
Learn more about the latest in non-small cell #LungCancer (NSCLC) with two new presentations at #ASCO25. Connect with us at booth 27021: spkl.io/6015ffeRJ
Douglas Lin, MD PhD retweeted
Benchmark study evaluating adequacy and success rates of comprehensive genomic profiling in tissue and plasma samples in a real-world setting. @DougLinMD
doi.org/10.1093/oncolo/oyae2…
Douglas Lin, MD PhD retweeted
Emerging questions and SWI/SNF deficient entities - excellent talk by Dr. Agaimy @pbpath @TheUSCAP #USCAP2025
Douglas Lin, MD PhD retweeted
Join @BrookeHowittMD June 9–12 in Hilton Head for Pathology on the Coast! Dive into #GynecologicPathology with engaging sessions & enjoy afternoons to unwind. ☀️🏖️ Early bird pricing ends March 31!
Register now: brnw.ch/21wRl9d
#GynPath #PathTwitter #CME
Douglas Lin, MD PhD retweeted
This awful-looking malignant neoplasm proved to be a malignant solitary fibrous tumor on molecular studies - I was not the one clever enough to order the STAT6, but it is patchy - the detection of the NAB2::STAT6 fusion was important.
Douglas Lin, MD PhD retweeted
A very relevant question for 🩸liquid biopsy: @ChristianRolfo et al. @IcahnMountSinai
🧬When can we trust a negative result from a ctDNA test and omit tissue biopsy?
🧬LB with ctDNA tumor fraction ≥1% accurately identifies true negative results in lung cancer, reducing the need for invasive tissue tests. For ctDNA TF <1%, follow-up tissue testing is needed!
@oncoalert @CCR_AACR @geoff_oxnard @isliquidbiopsy @MCristofanill @ASCO
aacrjournals.org/clincancerr…
Douglas Lin, MD PhD retweeted
New work on these enigmatic #GLI1 tumors. We found that even some bland, non-mitotically active cases can metastasize #BSTpath #pathX
@JCloutierMD @nathrodriguesMD @Greg_Charville @SintawatWang
Free download through Jan: authors.elsevier.com/a/1iFSK…
Douglas Lin, MD PhD retweeted
Interesting case from Dr. Michelle S. Hirsch. Diagnosis?
54 year old male with a 2.8 cm testicular mass.
Join Dr. Hirsch at our January Diagnostic Challenges in Urologic Pathology course in Palm Springs for this and many other cases. my.uscap.org/app/program/kD0…
Douglas Lin, MD PhD retweeted
Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate Cancer
buff.ly/44ZJjcH
@HougenHY @RyonGraf @DougLinMD @sanojpunnen @BrandonMahal
#prostatecancer #Medtwitter #UroSoMe #openaccess #openscience
Douglas Lin, MD PhD retweeted
QUEM TEM MAIS, TEM SEIS 🏆🏆🏆🏆🏆🏆
A meta é a seguinte, Nação: 6 mil curtidas nesse tweet e a gente libera os #Bastidores. Bora?
Douglas Lin, MD PhD retweeted
MMRd, NGS-based MSI, & TMB as predictive biomarkers for immune checkpoint inhibitor effectiveness for #EndometrialCancer
@DougLinMD @GynCancerMD
🆓 https://nitter.gq/t.co/5ZhstETB9d
@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @OncoAlert @IJGCfellows
Douglas Lin, MD PhD retweeted
Excited to share some great work on predicting genomic alterations from H&E lead by James Pao at FMI - @DougLinMD @BostonGenomics @PritiHegde nature.com/articles/s41598-0…
Douglas Lin, MD PhD retweeted
01/ Buckle up, everyone, it’s time for a Tweetorial. Been working on this one for a while. This time, I’ll focus on the most common mesenchymal malignancy of the digestive tract: gastrointestinal stromal tumor (GIST). #pathology #gipath #PathTwitter
Douglas Lin, MD PhD retweeted
Just in @CCR_AACR: Happy to report👉SPOP mutation as 1st treatment selection biomarker in mCSPC #ProstateCancer , predicts response to ARAT & not to docetaxel https://nitter.gq/t.co/aYH06Fb2WU @neerajaiims @EAntonarakis @RyonGraff @geoff_oxnard @OncoAlert @PCF_Science Tweetorial (1/10)
Douglas Lin, MD PhD retweeted
Wow!!! Really exciting news. Congrats, Team! Also, our accepted manuscript available online today at @CCR_AACR aacrjournals.org/clincancerr… SPOP mutations as a Predictive Biomarker for Androgen Receptor-Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
With @umangtalking @neerajaiims at the #ESMO22 poster session 👉Congrats for the GU Best poster award. Always amazing research from @Huntsman_GU team. @OncoAlert @urotoday @huntsmancancer
Douglas Lin, MD PhD retweeted
Really excited about this discovery from a great team including @Matt_Margolis @BrennanJDecker @DouglasMataMD @DougLinMD @geoff_oxnard
Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of aden… pubmed.ncbi.nlm.nih.gov/3597…
Douglas Lin, MD PhD retweeted
Pineal region tumor in a teenage male. Diagnosis? One picture is all you need! 🧐 #neuropath #PathTwitter #MedTwitter #pathboards #purplepath 🧠🔬
Douglas Lin, MD PhD retweeted
Hello and welcome to the Gross Case of the Week! The case this week demonstrates an uncommon tumor that can be found in some women. Can you name what is pictured here? #GrossCOTW #PathAssist #BWHGynPathSummer
1/4
















































